Last updated: February 17, 2026
Overview of NDC 10147-0892
NDC 10147-0892 is marketed as Rilzabrutinib. It is an experimental Bruton's tyrosine kinase (BTK) inhibitor developed primarily for autoimmune diseases, including immune thrombocytopenic purpura (ITP). As of 2023, Rilzabrutinib remains an investigational drug, with no FDA approval or commercial sales completed. Its market potential hinges on clinical trial outcomes and regulatory decisions.
Current Status and Development Pipeline
- Phase of Development: Rilzabrutinib is in Phase 3 trials targeting ITP, with some trials in autoimmune indications.
- Regulatory Status: Not approved by FDA or EMA. Applying for Breakthrough Therapy designation or accelerated approval in certain markets could influence its market entry timeline.
- Competitor Landscape: Other BTK inhibitors like Ibrutinib and Acalabrutinib are established in oncology but not yet in autoimmune indications—representing a niche market opportunity if approved.
Market Size and Potential
Autoimmune Disease Market
- Immune thrombocytopenic purpura (ITP)
- Global market size: Estimated at $600 million in 2022, with a compound annual growth rate (CAGR) of approximately 10% through 2028 [1].
- Patient population: Approximately 50,000–100,000 diagnosed US patients, with similar counts in Europe.
- Other autoimmune applications
- Rilzabrutinib’s potential extends to diseases like lupus, rheumatoid arthritis, and pemphigus.
- These combined markets could add an estimated $2–3 billion globally, assuming regulatory approval and favorable trial results.
Competitive Dynamics
- Existing treatments for ITP include corticosteroids, IVIG, thrombopoietin receptor agonists, and splenectomy.
- Rilzabrutinib’s advantage could derive from oral administration and targeted immunomodulation.
- Patient acceptance hinges on safety profile and efficacy over existing therapies.
Price Projections and Economic Considerations
Factors Influencing Price Points
- Development costs: Estimated at $1.5–$2 billion for complete clinical trials, regulatory approval, and commercialization [2].
- Market exclusivity: Data exclusivity duration in the US is five years, with patent protections potentially extending beyond 10 years.
- Pricing benchmarks: Oncology BTK inhibitors like Ibrutinib are priced at approximately $9,500–$11,000 per month.
- Therapeutic niche: Market pricing for autoimmune drugs tends to be lower; monoclonal antibodies such as Rituximab are priced around $3,000–$4,000 per dose.
Projected Pricing Range
- Initial launch: Estimated at $4,000–$5,000 monthly, considering autoimmune indication and competitive landscape.
- Long-term pricing: Could stabilize at $3,500–$4,500 per month if competition or biosimilars emerge.
Sales Volume Assumptions
- Year 1 post-launch: 10,000 patients globally, with sales reaching approximately $480 million annually at $4,000/month.
- Year 5: Market penetration could increase to 25,000–30,000 patients, leading to a revenue potential of $1.0–$1.4 billion annually.
Risks and Revenue Drivers
- Clinical outcomes: Positive trial results could accelerate approval and adoption.
- Regulatory hurdles: Delays or rejection could drastically reduce market opportunities.
- Pricing negotiations: Payers may negotiate discounts, affecting gross sales.
- Market uptake: Physician acceptance depends on efficacy, safety, and convenience.
Conclusion
Rilzabrutinib’s market prospects depend on successful clinical trials and regulatory approval. Pricing will likely be in the $3,500–$5,000 monthly range initially, with significant growth potential if proven effective across multiple autoimmune indications and achieving rapid market penetration.
Key Takeaways
- Rilzabrutinib (NDC 10147-0892) remains investigational, with potential in autoimmune diseases such as ITP.
- The global autoimmune market is expanding, projected to reach $2–3 billion for targeted therapies by 2028.
- Initial pricing likely around $4,000–$5,000 per month, with long-term revenues potentially exceeding $1 billion annually.
- Market entry hinges on positive clinical data, regulatory approval, and payer acceptance.
- Competitive landscape and safety profile are crucial for sustained market success.
FAQs
1. What is the primary indication for Rilzabrutinib?
It targets autoimmune conditions, mainly immune thrombocytopenic purpura (ITP), in clinical development.
2. When is Rilzabrutinib expected to gain approval?
Pending Phase 3 trial outcomes; FDA approval could occur within 1–2 years if successful.
3. How does Rilzabrutinib compare costing-wise to existing treatments?
Pricing will likely be lower than oncology BTK inhibitors, around $4,000–$5,000 per month, to compete in autoimmune markets.
4. What factors could impact Rilzabrutinib’s market success?
Clinical efficacy, safety profile, regulatory approval, payer negotiations, and physician acceptance.
5. Could Rilzabrutinib expand into other autoimmune diseases?
Yes, if trials for lupus, rheumatoid arthritis, or pemphigus show positive results, market size could increase substantially.
References
[1] Global Data. "Autoimmune Disease Market Forecast," 2022.
[2] Deloitte. "Pharmaceutical R&D Cost Analysis," 2021.
